Aegis assumed coverage on shares of Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) in a research note published on Tuesday morning. The firm issued a hold rating and a $15.00 target price on the biotechnology company’s stock.

MNTA has been the topic of a number of other reports. Zacks Investment Research cut Momenta Pharmaceuticals from a buy rating to a hold rating in a report on Wednesday, October 5th. JPMorgan Chase & Co. decreased their price target on Momenta Pharmaceuticals from $21.00 to $15.00 and set an overweight rating on the stock in a report on Friday, August 5th. Maxim Group reissued a sell rating and set a $6.00 price target on shares of Momenta Pharmaceuticals in a report on Thursday, November 3rd. Finally, Barclays PLC raised Momenta Pharmaceuticals from an equal weight rating to an overweight rating and raised their price target for the company from $13.00 to $19.00 in a report on Tuesday, October 11th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus target price of $16.10.

Momenta Pharmaceuticals (NASDAQ:MNTA) traded up 0.184% during trading on Tuesday, hitting $13.575. The stock had a trading volume of 126,602 shares. Momenta Pharmaceuticals has a 52-week low of $7.86 and a 52-week high of $18.26. The firm’s market cap is $936.09 million. The company has a 50-day moving average of $12.20 and a 200 day moving average of $11.63.

Momenta Pharmaceuticals (NASDAQ:MNTA) last released its earnings results on Wednesday, November 2nd. The biotechnology company reported ($0.26) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.29) by $0.03. The company had revenue of $299.14 million for the quarter, compared to the consensus estimate of $25.68 million. Momenta Pharmaceuticals had a negative return on equity of 26.55% and a negative net margin of 93.75%. Momenta Pharmaceuticals’s quarterly revenue was up 2067.7% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.44) earnings per share. On average, equities research analysts predict that Momenta Pharmaceuticals will post ($1.15) earnings per share for the current fiscal year.

Several hedge funds have recently made changes to their positions in the stock. Cornerstone Capital Management Holdings LLC. purchased a new stake in shares of Momenta Pharmaceuticals during the third quarter worth about $135,000. Candriam Luxembourg S.C.A. purchased a new stake in shares of Momenta Pharmaceuticals during the third quarter worth about $818,000. Patten Group Inc. purchased a new stake in shares of Momenta Pharmaceuticals during the third quarter worth about $148,000. Virtus ETF Advisers LLC raised its stake in shares of Momenta Pharmaceuticals by 14.4% in the third quarter. Virtus ETF Advisers LLC now owns 55,093 shares of the biotechnology company’s stock worth $644,000 after buying an additional 6,942 shares during the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Momenta Pharmaceuticals during the third quarter worth about $525,000. Hedge funds and other institutional investors own 81.62% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This report was first published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2016/11/23/momenta-pharmaceuticals-inc-mnta-coverage-initiated-by-analysts-at-aegis.html.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox (enoxaparin sodium injection).

5 Day Chart for NASDAQ:MNTA

Receive News & Stock Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.